GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Total Stockholders Equity

NFL Biosciences (XPAR:ALNFL) Total Stockholders Equity : €0.35 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences Total Stockholders Equity?

NFL Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €0.35 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NFL Biosciences's Book Value per Share for the quarter that ended in Dec. 2023 was €0.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NFL Biosciences's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.18.

NFL Biosciences Total Stockholders Equity Historical Data

The historical data trend for NFL Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NFL Biosciences Total Stockholders Equity Chart

NFL Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial 0.41 0.15 3.29 0.84 0.35

NFL Biosciences Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Total Stockholders Equity Get a 7-Day Free Trial 3.29 2.22 0.84 1.91 0.35

NFL Biosciences  (XPAR:ALNFL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NFL Biosciences's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.35-0)/8.10677
=0.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NFL Biosciences's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.062 + 0) / 0.35
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NFL Biosciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of NFL Biosciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NFL Biosciences (XPAR:ALNFL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Total Stockholders Equity
Comparable Companies
XPAR:ALTHX XPAR:ALPAT XPAR:ALHYG XPAR:ALINT XPAR:FALG XPAR:POXEL XPAR:ALVET XPAR:ALBPS XPAR:ALMDP XPAR:ALQGC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
82F:Germany
Address
199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170
Website
https://www.nflbiosciences.com/
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (XPAR:ALNFL) Headlines

No Headlines